Michael Zamloot
22Patents
8h-index
20Co-inventors
71Inventor score
Filing activity: Dec 5, 2008 → Nov 21, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8415401B2 | Oral pharmaceutical dosage forms | Human Necessities | 58 | Active |
| US8945614B2 | Oral drug delivery system | Human Necessities | 30 | Active |
| US8951556B2 | Oral drug delivery system | Human Necessities | 30 | Active |
| US8974821B2 | Oral drug delivery system | Human Necessities | 27 | Active |
| US9233160B2 | Oral drug delivery system | Human Necessities | 26 | Active |
| US9517271B2 | Oral drug delivery system | Human Necessities | 21 | Active |
| US9623017B2 | 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal | Chemistry; Metallurgy | 9 | Active |
| US9592204B2 | Oral pharmaceutical dosage forms | Human Necessities | 8 | Active |
| US9572885B2 | Compositions with a rheological modifier to reduce dissolution variability | Human Necessities | 7 | Active |
| US9655861B2 | Oral pharmaceutical dosage forms | Human Necessities | 6 | Active |
| US9555113B2 | Compositions with a rheological modifier to reduce dissolution variability | Human Necessities | 5 | Active |
| US9855333B2 | Compositions with a rheological modifier to reduce dissolution variability | Human Necessities | 2 | Active |
| US12065440B2 | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts | Chemistry; Metallurgy | 1 | Active |
| US11370791B2 | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts | Chemistry; Metallurgy | 1 | Active |
| US10206883B2 | Oral pharamaceutical dosage forms | Human Necessities | 0 | Active |
| US9339463B2 | Micronized opioid compositions having a specific particle size distribution | Human Necessities | 0 | Active |
| US9907851B2 | Compositions with a rheological modifier to reduce dissolution variability | Human Necessities | 0 | Active |
| US12391693B2 | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts | Chemistry; Metallurgy | 0 | Active |
| US10980799B2 | Crystalline salts of naloxone and naltrexone | Chemistry; Metallurgy | 0 | Active |
| US10300142B2 | Compositions with a rheological modifier to reduce dissolution variability | Human Necessities | 0 | Active |
| US11096936B2 | Cocrystals of naloxone and naltrexone | Chemistry; Metallurgy | 0 | Active |
| US9918982B2 | Oral drug delivery system | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.